FDA clears use of Lilly's COVID-19 antibody therapy for kids
The FDA authorization also allows the administration of the therapy as a preventive measure in children who are exposed to the virus.
A health worker holds up a vial of Imdevimab, an antibody cocktail designed to produce resistance to the coronavirus disease (COVID-19), at San Giuseppe Hospital, in Albano, Italy, April 22, 2021(photo credit: REUTERS/YARA NARDI)ByREUTERSUpdated:
